drugset / Trial / NCT00587457
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or Small Lymphocytic Lymphoma (SLL).
Timeline
- Start
- 2007-03-07
- Primary completion
- 2008-04-07
- Completion
- 2008-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 5 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 10 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 20 ug/kg | Intravenous |